1. Introduction {#s0005}
===============

Acute fibrinous and organizing pneumonia (AFOP) is a rare histologic interstitial pneumonia pattern that is histologically characterized by intra-alveolar fibrin "balls" and organizing pneumonia with a patchy distribution. It is associated with viral, bacterial, and fungal infections, connective tissue disorders, autoimmune diseases, certain drugs including amiodarone, everolimus, decitabine, and abacavir, and occupational/environmental exposures such as asbestos, various dusts, exotic animals, aerosol products, and coal; it may also be idiopathic in nature. Patients present with cough, dyspnea, or acute respiratory distress syndrome. Radiological findings demonstrate diffuse patchy opacities. The diagnosis requires a lung biopsy which can be obtained surgically, via bronchoscopy, or under ultrasound- or computed tomographic (CT) scan-guidance. The definitive management of this disease is still unknown; however, there is a role for steroids and other immunosuppressive agents [@bb0005].

We present the case of a man diagnosed with AFOP and describe his 30-month post-discharge course, the longest follow-up in the literature to our knowledge. In addition, we will also present the most comprehensive review of the AFOP literature. Patient characteristics, suspected etiology, diagnostic modality, treatments, and outcomes will be reported.

2. Case report {#s0010}
==============

A 60-year-old male smoker was transferred from an outside hospital presenting with progressively worsening dyspnea and blood-tinged sputum over the course of 2 months. He was otherwise healthy and reported a history of working with asbestos and fiberglass from 1975 to 1988, and recent occupational dust exposure. He complained of low grade fevers and sweats and denied weight loss, other significant exposures, recent travel, pets, and sick contacts. At an outside hospital, a chest x-ray showed bilateral diffuse opacities and small bilateral pleural effusions ([Fig. 1](#f0005){ref-type="fig"}A). A CT scan of the chest demonstrated diffuse bilateral ground glass densities ([Fig. 1](#f0005){ref-type="fig"}B). Bronchoscopy was performed and biopsies were negative for malignancy, granulomas, *Pneumocystis jirovecii* cysts, and trophozoites. Gram stain and culture, periodic acid--Schiff stain, and acid fast-bacilli culture were negative. Bronchoalveolar lavage (BAL) showed many red blood cells, few white blood cells, and no organisms. The BAL culture grew few *Candida albicans*. Routine laboratory work up was normal, except for an elevated white blood cell count. Laboratory work for rheumatoid factor, cold agglutinins, antinuclear antibodies, Scl-70 scleroderma antibody, and histone antibody were negative. In addition, HIV-1 and HIV-2, influenza A and B, urine *Legionella* antigen, and *Mycoplasma pneumoniae* IgG and IgM were negative. He received a 7-day course of antibiotics (ceftriaxone, azithromycin, and doxycycline) and methylprednisolone 125 mg IV every 6 hours for 6 days. Despite therapy, his symptoms did not improve and he was transferred to our hospital for further work up.Fig. 1A, Chest x-ray showing bilateral patchy infiltrates.B, Chest CT scan showing diffuse ground glass opacities.

On initial physical examination he was afebrile, tachypneic, and hypoxic, requiring 80% oxygen to achieve a SpO~2~ of 92%. Lung auscultation revealed diffuse rhonchi and rales. Additional tests performed at our institution included blood and sputum cultures, ANCA, Jo-1 antibody, glomerular basement membrane antibody, cyclic citrullinated peptide IgG and IgA, and creatine phosphokinase, which were negative. On admission to our hospital, methylprednisolone 60 mg IV every 6 hours was given for 2 days, and the dose was later increased to 125 mg IV every 6 hours. Two days later a steroid taper was initiated, decreasing the methylprednisolone dose to 60 mg IV every 6 hours for 5 days, and then prednisone 60 mg PO daily was started. He required oxygen with a high flow nasal cannula. On the fourth day of hospitalization, he underwent an anterior thoracotomy, right wedge lung biopsies, and right chest tube placement. He was brought intubated from the operating room for ventilator weaning in the intensive care unit and he was extubated on postoperative day 1. Specimens of the lung biopsy were sent for pathology, microbiology, and virology. The pathology demonstrated AFOP with a background of chronic interstitial pneumonia ([Fig. 2](#f0010){ref-type="fig"}A and B). A trichrome stain revealed fibrosis. Tissue specimens were negative for acid fast-bacilli, mycobacteria, fungi and cytomegalovirus. Gram stain and culture were also negative. However, an anaerobic and aerobic culture grew a coagulase negative *Staphylococci*. Sulfamethoxazole/trimethoprim was initiated on postoperative day 3. On repeat chest x-ray, the lungs appeared unchanged. The chest tube was eventually removed and he was discharged to pulmonary rehabilitation on prednisone 60 mg PO daily and continuous oxygen via nasal cannula at 3 L/min.Fig. 2A, Histology of AFOP with diffuse and patchy involvement.B, Histology of AFOP with intraalveolar fibrin balls.

Upon discharge, the patient was followed by the pulmonology team. Eight months after his hospital discharge, he experienced arthralgias and Raynaud's syndrome, and developed telangiectasias. On further evaluation, blood work was positive for antinuclear antibodies and Sjogren's syndrome antibody and he was diagnosed with an unspecified connective tissue disease (CTD). He was started on azathioprine, but because of an adverse reaction, his therapy was changed to mycophenolate mofetil 500 mg PO 3 tablets in the morning and 2 tablets at night. Over 2 years, several steroid tapers were attempted unsuccessfully. His symptoms worsened at lower doses. Thirty months after discharge he remains dependent on mycophenolate mofetil, prednisone 10 mg PO daily, and oxygen, requiring 4 L/min via nasal cannula at rest and during sleep, and 8 to 10 L/min via an oxymizer pendant with activity. He is currently on disability. Although his exercise tolerance improved after completing pulmonary rehabilitation, his functional status has not returned to his pre-illness baseline. He has been evaluated and listed for lung transplantation.

3. Discussion {#s0015}
=============

Acute fibrinous and organizing pneumonia (AFOP) is a rare histologic interstitial pneumonia pattern; as of 2015, there have been 111 cases reported in the literature ([Table 1](#t0005){ref-type="table"} ). Of these cases, 43 were male, 35 were female; gender was not specified in 33 cases. It most commonly occurred in patients in their fifth and sixth decade of life; however, there were 5 reports in children. In most cases, the etiology was unknown. Possible causes of AFOP include connective tissue disease, infections, environmental or occupational exposure, drug reactions, autoimmune disease, after organ transplantation, and cancers ([Table 1](#t0005){ref-type="table"}). In our case, possible etiologies include asbestos and fiberglass exposure, as well as connective tissue disease.Table 1Summary of patient characteristics, diagnosis, treatment, and outcome in AFOP from literaturePublicationPatient characteristicsProposed causeDiagnostic methodTreatmentOutcomeDuration of Follow-upStill on treatment at follow-up?Lopez-Cuenca et al [@bb0010]27 yo FMarden-Walker syndrome/sepsis/ARDSAutopsyCorticosteroids, antibiotics, mechanical ventilationDeath15 daysNABhatti et al [@bb0015]56 yo MIdiopathicSBCorticosteroids, mycophenolate mofetil, mechanical ventilationImproved12 monthsYesBeasley et al [@bb0005]77 yo M*Haemophilus influenza*SB or autopsy[⁎](#tf0005){ref-type="table-fn"}AntibioticsDeathNSNA33 yo MOccupational exposure (construction worker)/*Acinetobacter baumanii*SBAntibioticsImprovedNSNS55 yo MAnkylosing spondylitis/occupational exposure (zoologist exposed to exotic animals)/amiodaroneSBAntibioticsImprovedNSNS76 yo FEnvironmental (excessive hair spray)SBCorticosteroids, antibioticsImprovedNSNS74 yo MEnvironmental exposure (coalminer)SB or autopsy[⁎](#tf0005){ref-type="table-fn"}Furosemide, dopamine, mechanical ventilationDeathNSNA78 yo FPolymyositisSB or autopsy[⁎](#tf0005){ref-type="table-fn"}CorticosteroidsDeath (unrelated cause)NSNA58 yo FPossible fibromyalgiaSBAntibioticsImprovedNSNS47 yo MIdiopathicSBAntibioticsImprovedNSNS39 yo MKi-1 lymphomaSB or autopsy[⁎](#tf0005){ref-type="table-fn"}Corticosteroids, mechanical ventilationDeathNSNA59 yo FIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}Antibiotics, corticosteroids, mechanical ventilationDeathNSNA70 yo MIdiopathicSBAntibioticsImprovedNSNA72 yo FIdiopathicSBAntibiotics, corticosteroidsImprovedNSNS36 yo MIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}Mechanical ventilationDeathNSNA76 yo MIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}Antibiotics, corticosteroidsDeathNSNA65 yo FIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}AntibioticsDeathNSNA68 yo FIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}NADeathNSNA66 yo MIdiopathicSB or autopsy[⁎](#tf0005){ref-type="table-fn"}Antibiotics, corticosteroids, mechanical ventilationDeathNSNAGuimaraes et al [@bb0020]55yo FPrimary biliary cirrhosisSBCorticosteroidsImproved14 monthsYesRapaka et al [@bb0025]38 yo MHIVFTBBCorticosteroidsImprovedNSNSKobayashi et al [@bb0030]55 yo MChronic glomerulonephritisSBCorticosteroidsImproved3 monthsNSTzouvelekis et al [@bb0035]65 yo FIdiopathicSBCorticosteroids, antibioticsImproved3 monthsYesZhang et al [@bb0040]73 yo MIdiopathicUltrasound-guided percutaneous lung biopsyCorticosteroidsImproved1.5 monthsYesValim et al [@bb0045]39 yo FSystemic sclerosisSBCyclophosph-amide, corticosteroids, mechanical ventilationDeath3 daysNADamas et al [@bb0050]66 yo MIdiopathicSBAntibiotics, corticosteroids, cyclophosphamideImprovedNSNSYokogawa et al [@bb0055]52 yo FAbacavirSBAntibiotics, corticosteroids, discontinue AbacavirImprovedNSNSBalduin et al [@bb0060]47 yo MCollagen vascular diseaseSBCorticosteroids, azathioprine, noninvasive mechanical ventilationImprovedNSNSLee et al [@bb0065]60 yo MHematopoietic stem cell transplantation/Acute myelogenous leukemiaFTBBCorticosteroidsDeath61 daysNACanessa et al [@bb0070]60 yo FWhipple's diseaseSBAntibioticsImprovedNSNSVasu et al [@bb0075]64 yo MDecitabine/Acute myelogenous leukemia/myelodysplastic syndromeSBCorticosteroids, discontinuation of decitabineImprovedNSNSHariri et al [@bb0080]47 yo MSystemic lupus erythematosusSBCorticosteroids, cyclophosphamideImprovedNSYesHeo et al [@bb0085]40 yo MHIV/*Pneumocystisjirovecii*SBAntibiotics, corticosteroidsImproved8 monthsNoSantos et al [@bb0090]44 yo MIdiopathicSBSurgical resectionImprovedNSOtto et al [@bb0095]66 yo FInfluenza virus/history of double lung transplantAutopsyAntiviral, antibiotics, mechanical ventilation, ECMODeath11 monthsNARibera et al [@bb0100]69 yo F*Chlamydia pneumoniae*FTBBAntibiotics, steroids, mechanical ventilationDeath20 daysNACincotta et al [@bb0105]38 day old FARDS/RSVSBMechanical ventilationDeathNSNA10 month oldARDS/severe combined immunodeficiency/*Pneumocystis carinii* pneumoniaSBMechanical ventilationDeathNSNASverzellati et al [@bb0110]62 yo FPulmonary mycosis fungoidesSBCorticosteroidsImprovedNSNSCho et al [@bb0115]79 yo MIdiopathicSBCorticosteroidsImprovedNSNSSauter et al [@bb0120]66 yo FAnti-synthetase syndromeSBAzathioprine, mycophenolate, corticosteroidsImproved2 yearsYesWhite et al [@bb0125]1 patientEverolimusFTBBNSNSNSNSPrahalad et al [@bb0130]14 yo FJuvenile dermatomyositisSBAntibiotics, corticosteroids, IV immunoglobulin, cyclosporine, cyclophosphamide, oscillating mechanical ventilationDeath2 weeksNAHwang et al [@bb0135]6 patients with mean age of 68 yoSevere acute respiratory syndrome (SARS)AutopsyNSDeathNSNAQiu et al [@bb0140]5 patients, 2 male and 3 female, age 43-61 yoNSCT-guided percutaneous lung biopsyCorticosteroidsImprovedNSNSAl-Khouzaie et al [@bb0145]45 yo MNSLung biopsyCorticosteroidsImprovedNSNSLabarinas et al [@bb0150]10 yo MSevere aplastic anemia/fulminant hepatic failure (suspected to be autoimmune)Lung biopsyAntithymocyte globulin, cyclosporine, hematopoietic stem cell transplantImprovedNSNSMoreira et al [@bb0155]44 yo MNSSBSurgical resectionImprovedNSNoBawa et al [@bb0160]31 yo FIdiopathicLung biopsyCorticosteroids, antibioticsImproved9 monthsYesJarbou et al [@bb0165]70 yo MIdiopathicSBCorticosteroidsImproved6 monthsYesAlici et al [@bb0170]48 yo FGrade 2 primary graft dysfunction of lung transplantFTBBCorticosteroidsImproved1 weekYesFeng et al [@bb0175]64 yo M*Mycobacterium tuberculosis*Percutaneous needle lung biopsyCorticosteroids, anti-tuberculosis antibioticsImproved9 monthsNS84 yo MLung adenocarcinomaPercutaneous needle lung biopsy, surgical lung biopsyCorticosteroids, antibiotics, surgical resectionDeath due to brain metastasis10 monthsNAGarcia et al [@bb0180]46 yo MIdiopathicSBCorticosteroidsImprovedNSNSHara et al [@bb0185]70 yo MIdiopathicFTBBCorticosteroidsResolved3 monthsNS55 yo MIdiopathicSBCorticosteroidsResolved3 monthsNSKassir et al [@bb0190]53 yo F*Mycoplasma pneumoniae*Peripheral lung biopsyCorticosteroidsImproved2 weeksYesLococo etal [@bb0195]65 yo FIdiopathicSBCorticosteroidsResolved6 weeksNSPiciucchi et al [@bb0200]79 yo MAmiodaroneFTBBCorticosteroidsResolved3 monthsNSMittal et al [@bb0205]14 yo FIdiopathicCT-guided percutaneous transthoracic lung biopsyCorticosteroidsResolved1 monthNoRenaud-Picard et al [@bb0210]22 yo MCystic fibrosis; lung transplantFTBBCorticosteroids, antibiotics, re-transplantation of lungsImproved2 yearsNoAkhtar et al [@bb0215]68 yo FIdiopathicCT-guided biopsyCorticosteroidsImproved2 monthsYesFeinstein et al [@bb0220]10 patients, 4 M, 6 F, average age 59.6 yoNSSBCorticosteroids6 patients improved; Death in 4 patients(unrelated to AFOP)NSNSRajan et al [@bb0225]42 yo MAcute myelogenous leukemia/AspergillosisSBAntifungalResolved5 monthsNoParaskeva et al [@bb0230]22 patientsLung transplantFTBBAntibiotics, antifungals, corticosteroidsDeathMedian time to death 94 days after diagnosisNABierach et al [@bb0235]4 patientsLung transplantNSCorticosteroidsNSNSNSOskuei et al [@bb0240]71 yo MDecitabine/myelodysplastic syndromeSBCorticosteroids, antibiotics, discontinuation of decitabineImprovedNSNSHankollari et al [@bb0245]36 yo MBleomycinFTBBCorticosteroidsImprovedNSNSRafii et al [@bb0250]55 yo FIdiopathicSBCorticosteroidsImprovedNSNS[^1][^2]

Patients present with progressive dyspnea, cough, hemoptysis, fever, fatigue, or acute respiratory distress syndrome. Patients can present with an acute, rapidly progressing form associated with poor outcomes, or more commonly, a subacute form, with a gradual onset of symptoms and a more favorable prognosis [@bb0005], [@bb0010], [@bb0015]. Poor outcomes are associated with patients requiring mechanical ventilation [@bb0005]. Of the 51 deaths reported in the literature, 6 were unrelated to AFOP [@bb0005], [@bb0010], [@bb0045], [@bb0065], [@bb0095], [@bb0100], [@bb0105], [@bb0130], [@bb0135], [@bb0175], [@bb0220], [@bb0230]. Of those that died, 12 required mechanical ventilation; in 37 cases, the use of mechanical ventilation was not specified. In the cases summarized in [Table 1](#t0005){ref-type="table"}, death resulted in 8 patients with viral infections (SARS, influenza virus, RSV), 2 patients with bacterial infections, 1 patient with environmental exposure, 1 patient with cancer, 1 patient following stem cell transplant, 1 patient with a combined picture of sepsis, ARDS, and developmental disorder, 22 patients after double-lung transplant and chronic allograft dysfunction, 2 patients with autoimmune diseases, and 7 patients in whom AFOP was idiopathic [@bb0005], [@bb0010], [@bb0045], [@bb0065], [@bb0095], [@bb0100], [@bb0105], [@bb0130], [@bb0135], [@bb0230]. The time to death was not reported in a majority of the cases; death occurred in less than 1 month in 4 patients, and less than 1 year in 24 patients [@bb0010], [@bb0045], [@bb0065], [@bb0095], [@bb0100], [@bb0130], [@bb0230]. Our patient had a subacute onset of the illness, with symptoms developing over 2 months. He required mechanical ventilation for less than 24 hours postoperatively. His symptoms improved with immunosuppressants, but he remains dependent on steroids, oxygen, and immunosuppressive medication for more than 2 years after diagnosis.

The diagnosis of AFOP is challenging. The radiological findings for AFOP are not diagnostic, and may vary. The most common radiological findings are diffuse, patchy opacities with both peripheral and bilateral distribution; it may be limited to the lung bases [@bb0005], [@bb0010], [@bb0015]. CT scan images may show the lesion as a solitary nodule with air bronchograms with progression to diffuse lung opacities [@bb0030]. In addition, the images may appear similar to other lung diseases such as interstitial pneumonia, pulmonary edema, and infectious pneumonia [@bb0045]. Our patient's chest x-ray showed bilateral pleural effusions and bilateral diffuse opacities. His chest CT scan showed diffuse bilateral ground glass densities; these findings were nonspecific and suggestive of a broad differential diagnoses. The diagnostic work up of AFOP may include BAL, but a lung biopsy provides the definitive diagnosis [@bb0005], [@bb0010]. Of the cases reviewed, 24 patients underwent BAL before pathological diagnosis. In all cases, the BAL was inconclusive [@bb0015], [@bb0020], [@bb0030], [@bb0035], [@bb0050], [@bb0055], [@bb0065], [@bb0075], [@bb0080], [@bb0090], [@bb0095], [@bb0100], [@bb0130], [@bb0165], [@bb0170], [@bb0180], [@bb0185], [@bb0190], [@bb0200], [@bb0210], [@bb0240], [@bb0245], [@bb0250]. In 8 patients, 7 of whom underwent transbronchial biopsy [@bb0015], [@bb0020], [@bb0030], [@bb0045], [@bb0165], [@bb0205], [@bb0235] and 1 who had a transthoracic biopsy [@bb0155], the results were inconclusive and required further diagnostic work up. The diagnosis of AFOP was made by surgical lung biopsy in 52 patients, transbronchial lung biopsy in 9 patients, percutaneous needle biopsy in 2 patients, image-guided (CT- or ultrasound-guided) percutaneous lung biopsy in 8 patients, peripheral lung biopsy in 1 patient, unspecified lung biopsy techniques in 3 patients, and autopsy in 10 patients [@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250]. Our patient's BAL and bronchoscopic biopsy were inconclusive; the diagnosis was made with surgical lung biopsy. To make a definitive diagnosis of AFOP, histopathologic evaluation is required [@bb0005].

The major histopathologic features of AFOP are intra-alveolar fibrin "balls", organizing pneumonia, and a patchy distribution within the lung parenchyma. It involves up to 90% of the alveolar spaces within a tissue sample. Minor features that may be associated with AFOP include inflammatory changes of the alveolar walls surrounding the areas of fibrin, myxoid connective tissue in the alveolar septum, type 2 pneumocyte hyperplasia, and minimal changes in the lung tissue areas without fibrin. It does not demonstrate hyaline membranes and lacks eosinophils, which distinguishes it from diffuse alveolar damage and eosinophilic pneumonia, respectively. Although fibrin deposition has been associated with diffuse alveolar damage, it is not the prominent feature and does not display the intra-alveolar fibrin ball pattern. In addition, diffuse alveolar damage is associated with diffuse changes, while AFOP presents in a patchy distribution. AFOP does not consist of granulomatous inflammation, bronchopneumonia, or abscess formation [@bb0005].

An ideal treatment of AFOP has not been reported; it has been treated with antibiotics, corticosteroids, and immunosuppressants (mycophenolate mofetil, azathioprine, and cyclophosphamide) with varying responses [@bb0005], [@bb0015], [@bb0050], [@bb0080], [@bb0130]. Corticosteroids are the most common and successful treatment modality described in the literature [@bb0215]. Akhtar et al [@bb0215] recommended methylprednisolone 60 mg every 6 to 8 hours for the first 5 days, followed by a gradual taper and a maintenance dose of 40 mg daily for 3 months. Other therapeutic regimens described included methylprednisolone 0.5 to 1 mg/kg per day IV followed by prednisone 0.5 to 1 mg/kg per day which is gradually tapered [@bb0015], [@bb0020], [@bb0030], [@bb0215]. The exact duration of therapy is unknown, and is based on the patient's clinical course and underlying etiology. Some patients return to baseline within months of treatment [@bb0085], [@bb0205], [@bb0225]. Other patients experienced worsening of symptoms during steroid tapers or noncompliance with treatment; improvement was noted when higher doses were resumed [@bb0035], [@bb0160], [@bb0215]. Treatment may be as long as 2 years [@bb0005], [@bb0015], [@bb0020], [@bb0050], [@bb0120]. From our literature review, the follow-up course of only 19 patients was reported and ranged from 2 weeks to 2 years [@bb0015], [@bb0020], [@bb0030], [@bb0035], [@bb0040], [@bb0085], [@bb0120], [@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0185], [@bb0195], [@bb0200], [@bb0205], [@bb0215], [@bb0225], [@bb0235]. Only 4 reports gave information on the patients' condition after 1 year [@bb0015], [@bb0020], [@bb0120], [@bb0210]. Ten patients were still receiving treatment at the time of follow-up, 3 patients completed treatment and were asymptomatic, and in 6 patients it was not specified whether or not they were still receiving therapy at the time of follow-up. Fifteen patients received only corticosteroids. One patient required corticosteroids and anti-tuberculosis antibiotics [@bb0175], and 1 patient improved after 5 months with only oral antifungal therapy [@bb0230]. Two patient required immunosuppressive agents such as cyclophosphamide, azathioprine, and mycophenolate mofetil in addition to corticosteroids [@bb0015], [@bb0120]. Of the 4 cases that reported on the patient's condition over 2 years, 3 patients remained on therapy at 1 year, 14 months, and 2 years of follow-up [@bb0015], [@bb0020], [@bb0120]; treatment was not specified at 2-year follow-up in 1 patient [@bb0210]. None of the cases in the literature specified whether the patients were oxygen-dependent on discharge or at follow-up. Our patient was discharged on a steroid taper; however, he experienced relapses with decreased doses, requiring resumption of higher doses. After his diagnosis of a connective tissue disease, mycophenolate mofetil was added to his therapeutic regimen. At 30 month follow-up, he continues to require immunosuppressant therapy, remains oxygen-dependent, and has been listed for lung transplantation.

Patients diagnosed with autoimmune or collagen vascular diseases may benefit from immunosuppressant therapy in addition to steroids. Cyclophosphamide and steroids were used to treat AFOP in patients with systemic sclerosis and systemic lupus erythematosus [@bb0045], [@bb0080]. In addition to steroids, azathioprine was used to treat a patient with collagen vascular disease and AFOP [@bb0060]. Sauter et al used azathioprine, mycophenolate mofetil, and steroids in the treatment for a patient with AFOP and anti-synthetase syndrome [@bb0120]. Prahalad et al described a case of AFOP diagnosed in the setting of juvenile dermatomyositis in which the patient continued to decline despite therapy with azithromycin and increased doses of methylprednisolone. She received intravenous immunoglobulin (2 g/kg), cyclosporine 5 mg/kg IV, and cyclophosphamide 500 mg/kg IV. She eventually required mechanical and oscillating mechanical ventilation but died after a massive pneumothorax [@bb0130]. Mycophenolate mofetil and cyclophosphamide have also been reported in idiopathic cases of AFOP, resulting in improved outcomes [@bb0015], [@bb0050]. Mycophenolate mofetil has been used to treat scleroderma-related interstitial lung disease and cyclophosphamide-refractory lupus nephritis. It is safe and effective in maintaining lung function in interstitial lung diseases associated with CTD [@bb0015]. It may be a useful adjunct to steroids in patients with associated autoimmune diseases and CTD.

Other therapeutic interventions include drug discontinuation, surgical resection, and organ transplantation. In cases caused by a medication (amiodarone, decitabine, abacavir, and bleomycin), treatment with corticosteroids and discontinuation of the drug resulted in improvement of symptoms [@bb0055], [@bb0075], [@bb0200], [@bb0240], [@bb0245]. There were 2 reports of surgical lung resection in the management of AFOP, without medical management, with subsequent improvement of symptoms [@bb0090], [@bb0155]. Surgical resection may be an additional treatment option in the management of AFOP if the disease is relatively localized.

AFOP has been described following organ transplantation; however, organ transplantation may be indicated to treat AFOP refractory to medical treatment. AFOP developed in 1 patient after an allogenic hematopoietic stem cell transplantation for the treatment of AML and in 23 patients after double-lung transplantation. All of the patients failed treatment with antibiotics, steroids, and immunosuppressants and expired [@bb0065], [@bb0095], [@bb0230]. Four patients developed AFOP after lung transplantation and were treated with immunosuppressive agents and corticosteroids but the long-term outcome was not specified [@bb0235]. Alici et al reported a patient with AFOP associated with grade 2 primary graft dysfunction of a lung transplant whose condition improved after corticosteroid treatment; however, the follow-up duration was only 1 week [@bb0170]. Labarinas et al described a case of AFOP in the setting of aplastic anemia and fulminant liver failure, suspected to be autoimmune in nature. There was no response to treatment with antithymocyte globulin or cyclosporine. Disease resolution occurred after hematopoietic stem cell transplant [@bb0150]. Renaud-Picard et al described a patient with cystic fibrosis who received a lung transplant. After 42 months, he experienced respiratory failure unresponsive to antibiotics and steroids. He underwent a bilateral lung retransplantation, and surgical pathology of the explanted lungs revealed AFOP. At 2-year follow-up, the patient was reportedly doing well [@bb0210]. At 30 months of follow-up, our patient remains dependent on immunosuppressive agents, and was listed for lung transplantation after he experienced clinical worsening and increased oxygen requirements.

Although case reports are considered to be at the bottom of the hierarchy of what is regarded as reliable evidence for basing clinical decisions, there is important knowledge that can be obtained from them [@bb0255]. The value of publishing case series and reviews is to educate providers on conditions which are rare, but may be more prevalent than expected. It informs clinicians of the diagnostic tools necessary to make the diagnosis, and provides them with treatment options that cannot be tested by randomized controlled trials because of the small number of subjects who have the rare disease [@bb0260]. It provides information on the clinical course of the disease and what therapeutic interventions have failed and succeeded. The goal of this case report and review is to provide clinicians with the presentation, diagnosis, and management of AFOP, a condition which may be more prevalent than we suspect. We presented the clinical presentation, radiological findings, diagnostic approach, associated conditions and how they affect management, and reported treatment options which have failed and succeeded. The literature does not clearly define the duration of the disease course or treatment, especially when it is associated with autoimmune, collagen vascular, or connective tissue disease. In addition, we describe that the disease course may be lengthy and may not resolve with medical management alone, and surgical intervention may be necessary. Through our literature review, we discovered localized disease may be curative by surgical resection, and lung transplantation may be considered in disease refractory to medical treatment with good long-term outcome.

4. Conclusion {#s0020}
=============

The treatment and long-term outcome of acute fibrinous and organizing pneumonia are not well defined. In the case presented, the patient was admitted with progressively worsening dyspnea and cough over 2 months and a ground glass appearance of lungs on CT scan. The diagnosis of AFOP was made by open lung biopsy and histology. His condition was complicated by a diagnosis of CTD. Thirty months after diagnosis he remains dependent on steroids, immunosuppressive agents, oxygen, and has been listed for lung transplantation. Our extensive literature review describes the associated medications and conditions with the disease, diagnostic modalities, various treatment strategies, and outcomes of AFOP. Definitive management of this illness is not yet clearly defined. Treatment includes steroids, immunosuppressive agents, and potentially surgical lung resection and organ transplantation. There are few studies which report the long-term outcomes of these patients. To date, we present the longest follow-up of a patient diagnosed with AFOP. It is important to raise awareness of this disease, so symptoms and radiological findings may be identified and lead to appropriate diagnostic tests and management. Further reports of therapeutic management and long-term outcomes are required.
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[^1]: yo, years old; F, female; M, male; SB, surgical biopsy; FTBB, fiberoptic transbronchial biopsy; NS, not specified; NA, not applicable; ARDS, adult respiratory distress syndrome; RSV, respiratory syncytial virus; HIV, human immunodeficiency virus; ECMO, extracorporeal membrane oxygenation.

[^2]: Beasley et al reported that 15 patients had open lung biopsies to confirm the diagnosis, and 2 patients had the diagnosis made on autopsy. It was not specified which of the patients had the diagnosis made on autopsy.
